Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 21;8:489. doi: 10.3389/fphar.2017.00489

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Yu, Zhang, Jin, Zhang, Yan, Yang, Ye and Ma.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of toddalolactone on PAI-1 activity. (A) Inhibition of PAI-1 activity by toddalolactone as determined by chromogenic assay. Data are the means ± SEs from four independent experiments. (B) Inhibition of PAI-1/uPA complex formation by toddalolactone. PAI-1 and uPA were incubated without or with the indicated concentrations of toddalolactone and then subjected to SDS-PAGE analysis. (C) Effect of toddalolactone on uPA-mediated lysis of fibrin clots. The fibrin clot was treated with uPA+PAI-1 only () or with 30 μM (), 60 μM (), 125 μM (), 250 μM () and 500 μM () of toddalolactone, or by uPA only (). (D) Effect of toddalolactone on uPA activity in the presence of PAI-1. Data are the means ± SEs from five experiments, each carried out in duplicate. “^∗” and “^∗∗” indicate significantly different from the control (no toddalolactone) at the P < 0.05 and P < 0.01 level, respectively.

Inline graphic — Effect of toddalolactone on PAI-1 activity. (A) Inhibition of PAI-1 activity by toddalolactone as determined by chromogenic assay. Data are the means ± SEs from four independent experiments. (B) Inhibition of PAI-1/uPA complex formation by toddalolactone. PAI-1 and uPA were incubated without or with the indicated concentrations of toddalolactone and then subjected to SDS-PAGE analysis. (C) Effect of toddalolactone on uPA-mediated lysis of fibrin clots. The fibrin clot was treated with uPA+PAI-1 only () or with 30 μM (), 60 μM (), 125 μM (), 250 μM () and 500 μM () of toddalolactone, or by uPA only (). (D) Effect of toddalolactone on uPA activity in the presence of PAI-1. Data are the means ± SEs from five experiments, each carried out in duplicate. “^∗” and “^∗∗” indicate significantly different from the control (no toddalolactone) at the P < 0.05 and P < 0.01 level, respectively.